Search results for "Retreat"

showing 10 items of 90 documents

Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).

2007

Background: Trastuzumab is widely used as the treatment of choice for HER2-positive metastatic breast cancer (MBC). Patients and methods: Seventy patients, median age 57 years and range 31-81 years, were included in our retrospective analysis with the aim to evaluate safety and activity of trastuzumab-containing therapies. Results: We observed for first-line treatment response rate (RR) 41%, stable disease (SD) 47% and time to progression (TTP) 8 months (range 1-44). Corresponding numbers for second line were RR 23%, SD 62% and (TTP) 9 months (range 3-23) and beyond second line RR 22%, SD 78% and (TTP) 9 months (range 4-19). Overall survival was 19.2 months (3-62 months). The median cumulat…

OncologyAdultmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionscardiac safety clinical experience heavily pretreated women metastatic breast cancer retrospective analysis trastuzumabAntineoplastic AgentsBone NeoplasmsBreast NeoplasmsSoft Tissue NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticMetastasisBreast cancerTrastuzumabcardiac safety; clinical experience; heavily pretreated women; metastatic breast cancer; retrospective analysis; trastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansskin and connective tissue diseasesAdverse effectneoplasmsAgedRetrospective StudiesAged 80 and overEjection fractionbusiness.industryCumulative doseAntibodies MonoclonalHematologyMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerSurgeryTreatment OutcomeOncologyFemalemedicine.symptombusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

2016

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab (Cycle 1; 300 mg) plus FC every 4 weeks for six cycles. Median C(max) and C(trough) values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C(max) and C(trough) values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas …

OncologyMaleCancer ResearchLymphomaDrug ResistanceMedizinKaplan-Meier EstimatePharmacologychemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocols80 and overChronicNeoplasm MetastasisLenalidomideCancerAged 80 and overUnivariate analysisLeukemiaRemission InductionAntibodies MonoclonalHematologyphase IIMiddle AgedLymphocyticThalidomideFludarabineClinical trialTreatment OutcomeOncologyTolerability6.1 Pharmaceuticals030220 oncology & carcinogenesisRetreatmentMathematikRituximabFemalePatient SafetyRefractory Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemiamedicine.drugAdultmedicine.medical_specialtyCyclophosphamidelenalidomideClinical Trials and Supportive ActivitiesClinical SciencesImmunologyCmaxAntineoplastic AgentsNeutropeniaOfatumumabAntibodies Monoclonal HumanizedDrug Administration ScheduleArticle03 medical and health sciencesRare DiseasesClinical ResearchChemoimmunotherapyInternal medicinemedicineImmunologic FactorsAnimalsHumansIn patientAdverse effectLenalidomideAgedNeoplasm StagingChromosome Aberrationsbusiness.industryB-CellEvaluation of treatments and therapeutic interventionsmedicine.diseaseHaresLeukemia Lymphocytic Chronic B-CellDiscontinuationClinical trialchemistryDrug Resistance NeoplasmNeoplasmbusinessCLL030215 immunology
researchProduct

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

2012

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic li…

OncologyMaleLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntibodieCetuximab; Clinical trial; Colorectal neoplasms; Phase II; RetreatmentDrug ResistanceCetuximabadverse effects/pharmacology/therapeutic useAdult; Aged; 80 and over; Antibodies; Monoclonal; administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects/pharmacology/therapeutic use; Camptothecin; administration /&/ dosage/analogs /&/ derivatives; Colorectal Neoplasms; drug therapy/mortality/pathology; Disease-Free Survival; Drug Resistance; Neoplasm; Exanthema; chemically induced; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; drug therapy/mortality/secondary; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment OutcomeColorectal NeoplasmKaplan-Meier EstimateAntineoplastic Combined Chemotherapy ProtocolsMonoclonal80 and overProspective cohort studyadministration /&/ dosageAged 80 and overCetuximabLiver NeoplasmsAntibodies MonoclonalHematologyMiddle AgedChemotherapy regimenPhase IIClinical trialTreatment OutcomeOncologyLiver NeoplasmLymphatic MetastasisRetreatmentchemically inducedFemaleColorectal Neoplasms/ dosage/analogs /&ampmedicine.drugHumanAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedIrinotecanAntibodiesDisease-Free SurvivalColorectal neoplasmdrug therapy/mortality/secondarySDG 3 - Good Health and Well-beingInternal medicineadministration /&/ dosage/analogs /&/ derivativesmedicine/ dosageHumansProgression-free survivalneoplasmsAgeddrug therapy/mortality/pathologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryLymphatic MetastasiExanthemamedicine.diseasedigestive system diseasesIrinotecanClinical trialLung Neoplasm/ derivativeDrug Resistance Neoplasmadministration /&ampNeoplasmCamptothecinbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic …

2015

Abstract Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183). Experimental Design: Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Progression-free survival (PFS) and overall survival (OS) we…

OncologyNeuroblastoma RAS viral oncogene homologAdultMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyColorectal cancerPopulationDNA Mutational AnalysisLeucovorinmedicine.disease_causeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicinePanitumumabHumansNeoplasm MetastasiseducationAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studybusiness.industryPanitumumabCancerAntibodies MonoclonalExonsMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesIrinotecanGenes rasTreatment OutcomeOncologyMutationRetreatmentFOLFIRICamptothecinFemaleKRASFluorouracilHuman medicinebusinessColorectal Neoplasmsmedicine.drugClinical cancer research
researchProduct

Multicentric, multifocal, and recurrent osteoid osteoma of the hip: first case report.

2019

Abstract Background Osteoid osteoma is a benign bone-forming tumour, which very unfrequently has multifocal or multicentric presentation. We report the first known case of a multicentric, multifocal and recurrent osteoid osteoma treated using radiofrequency ablation. Case presentation A 39-year-old man with two-year history of left hip pain was admitted at our Institution. The pain was more intense during the night and partially relieved by salicylates. Pelvis CT demonstrated two lytic lesions (8 and 7 mm, respectively) with surrounding sclerotic reactive bone, both with a central focal area of high attenuation, located in the femoral neck and along the anterior portion of the acetabulum, r…

Osteoid osteomamusculoskeletal diseasesAdultMalemedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemRadiofrequency ablationBiopsyOsteoma OsteoidBone NeoplasmsCase Reportlaw.inventionLesion03 medical and health sciences0302 clinical medicineRheumatologylawMedicineHumansOrthopedics and Sports MedicineComputed tomographyPelvisFemoral neck030203 arthritis & rheumatology030222 orthopedicsRadiofrequency AblationHipmedicine.diagnostic_testbusiness.industryFemur NeckMagnetic resonance imagingAcetabulummedicine.diseaseAcetabulumMagnetic Resonance ImagingPosterior columnbody regionsmedicine.anatomical_structureTreatment OutcomeOsteoid osteomaRetreatmentRadiologylcsh:RC925-935medicine.symptomNeoplasm Recurrence LocalbusinessTomography X-Ray ComputedBMC musculoskeletal disorders
researchProduct

How Effective and Safe Is Bronchial Thermoplasty in “Real Life” Asthmatics Compared to Those Enrolled in Randomized Clinical Trials?

2016

There is limited information on the efficacy and safety of bronchial thermoplasty (BT) inreal life. We evaluated the outcomes of the randomized clinical trials for BT in severe asthmatics, in whom the exclusion criteria were not strictly controlled. A case series of seven asthmatics (M/F: 4/3; age:54.6±2.9years) is reported. Subjects had a statistically significant improvement in AQLQ (from a mean of3.96±1.1to4.5±1.2and5.5±0.6after 6 and 12 months of treatment;p=0.0007) and in the ACQ score (from2.77±0.8to1.83±1.2and1.5±0.8after 6 and 12 months;p<0.001). In the year after BT, severe exacerbations, salbutamol use, and OCS use were significantly lower compared with the 1-yr pretreatment pe…

Pediatricsmedicine.medical_specialtyPretreatment PeriodArticle SubjectMEDLINElcsh:MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicineIn real life030212 general & internal medicineBronchial ThermoplastyGeneral Immunology and MicrobiologyBronchial thermoplastybusiness.industrylcsh:RGeneral MedicineAsthma030228 respiratory systemClinical StudySalbutamolbusinessmedicine.drugBioMed Research International
researchProduct

Historia Domu Rekolekcyjnego Konferencji Episkopatu Polski "Księżówka" w Zakopanem w latach 1910-1945

2016

W artykule została przedstawiona droga do zrealizowania, podjętego w 1891 r., przez Stowarzyszenie Domu Zdrowia dla Kapłanów w Zakopanem założenia, budowy domu wspólnoty, z uwzględnieniem bazy zakładu leczniczego. Obiekt przyjmował różną formułę: od domu dla księży w celach zdrowotnych, turystycznych po współczesne funkcje rekolekcyjno-szkoleniowe; od przeznaczenia dla osób wyłącznie duchownych, po szeroką ofertę korzystania z domu przez osoby świeckie. Tekst wprowadza w atmosferę panującą w „Księżówce” w czasach zaboru austriackiego, w II Rzeczypospolitej oraz w okresie okupacji hitlerowskiej.

Polish Bishop’s ConferenceZakopaneCatholic Church in Polanddomy rekolekcyjneKościół w PolsceKonferencja Episkopatu Polskiretreat houseStudia Teologiczno-Historyczne Śląska Opolskiego
researchProduct

Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C rea…

2019

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/13…

Resistance testmedicine.medical_specialtyHepatologybusiness.industryGastroenterologyDAA failurVironet C.NS5ARegimenInternal medicinemedicineretreatmentNS5AbusinessDigestive and Liver Disease
researchProduct

Valorisation of SWRO brines in a remote island through a circular approach: Techno-economic analysis and perspectives

2022

Nowadays, small remote islands rely heavily on desalination technologies to overcome freshwater scarcity. Unfortunately, these technologies are accompanied by the production of brines which can affect the receiving water bodies i.e., the aquatic ecosystem. Yet, it is extremely appealing how such brines constitute an abundant source of valuable raw materials (such as magnesium). In this work, a novel hybrid system is introduced to capture the value of seawater reverse osmosis (SWRO) brines produced in the minor Sicilian island of Pantelleria. The “Minimal Liquid Discharge” (MLD) process consists of: (i) Nanofiltration NF (separation of bivalent from monovalent ions), (ii) Mg Reactive Crystal…

Settore ING-IND/26 - Teoria Dello Sviluppo Dei Processi ChimiciCircular economy Brine management Mineral recovery ZLD MLDcrystallizationplantsMechanical EngineeringGeneral Chemical Engineeringcircular economywaternanofiltration membranesGeneral Chemistrypretreatmentzldmineral recoverycoal-mine brinebrine managementseawater desalinationmldsalt productionGeneral Materials ScienceconcentratetechnologiesWater Science and TechnologyDesalination
researchProduct

Combustion properties of spruce black liquor droplets : Sulfur-free pulping and influence of hot-water pretreatment

2016

Hot-water pretreatment of lignocellulosics prior to sulfur-free alkaline pulping is an interesting approach for recovering value-added carbohydrate- and lignin-derived materials. This paper investigated the chemical composition variations and combustion properties of the black liquors (BLs) from three different cooking processes: two sulfur-free soda-anthraquinone (soda-AQ) and oxygen-alkali (O2-NaOH) cooks and kraft cook, before and after hot-water pretreatment of the spruce sawdust. Relatively less aliphatic acids but more lignin were present in the BLs after hot-water pretreatment as cooking time prolonged. In general, the burning time decreased as follows: soda-AQ BL > O2-NaOH BL ≅ kraf…

Waste management020209 energycombustion propertieshot-water pretreatmenteducationtechnology industry and agriculturesulfur-free pulpingchemistry.chemical_elementfood and beveragesForestrymustalipeä02 engineering and technologyCombustionPulp and paper industrySulfurchemistryhemic and lymphatic diseaseskuuset0202 electrical engineering electronic engineering information engineeringEnvironmental scienceGeneral Materials ScienceBlack liquor
researchProduct